 |
34 Diseases |  |
9 Trials |
|
9 Trials |  |
673 News |  |
| «12345678» |
- ||||||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Sep 16, 2014
P3, N=707, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed
- |||| efavirenz / Generic mfg.
Trial completion: Treatment of Acute HIV With Emtricitabine, Tenofovir and Efavirenz (CID 0805) (clinicaltrials.gov) - Sep 11, 2014
P4, N=90, Completed, Sponsor: University of North Carolina, Chapel Hill
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial primary completion date, Head-to-Head: SALIF: A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (clinicaltrials.gov) - Aug 15, 2014
P3, N=426, Recruiting, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Completed Trial primary completion date: Jul 2014 --> Oct 2015
- ||||||| emtricitabine / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial completion, Monotherapy: DREAM: Evaluation of a Lopinavir/Ritonavir Monotherapy vs a Triple Therapy as Maintenance Regimens in HIV-1 Infected Patients (clinicaltrials.gov) - Jun 27, 2014
P2/3, N=420, Completed, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Trial primary completion date: Jul 2014 --> Oct 2015 Active, not recruiting --> Completed
- Isentress (raltegravir) / Merck (MSD)
Phase classification: Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection (clinicaltrials.gov) - Jun 12, 2014
P=N/A, N=20, Completed, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Phase classification: P4 --> P=N/A
- stavudine / Generic mfg., zidovudine / Generic mfg.
Trial completion date, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - May 6, 2014
P4, N=70, Recruiting, Sponsor: Tufts University
Phase classification: P4 --> P=N/A Trial completion date: Jun 2014 --> Aug 2014
- stavudine / Generic mfg., zidovudine / Generic mfg.
Trial primary completion date, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - May 6, 2014
P4, N=70, Recruiting, Sponsor: Tufts University
Trial completion date: Jun 2014 --> Aug 2014 Trial primary completion date: Mar 2014 --> Aug 2014
- | Enrollment open, IO biomarker, Metastases: Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS (clinicaltrials.gov) - Apr 28, 2014
P3, N=706, Recruiting, Sponsor: AIDS Clinical Trials Group
Trial primary completion date: Mar 2014 --> Aug 2014 Not yet recruiting --> Recruiting
- ||||| Tybost (cobicistat) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment closed: Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (clinicaltrials.gov) - Apr 20, 2014
P3, N=1500, Active, not recruiting, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment change: Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV Incidence (clinicaltrials.gov) - Apr 17, 2014
P=N/A, N=22000, Recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting --> Active, not recruiting N=5000 --> 22000
- ||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion date: Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Apr 15, 2014
P3, N=700, Active, not recruiting, Sponsor: Gilead Sciences
N=5000 --> 22000 Trial completion date: Apr 2014 --> Jul 2014
- Isentress (raltegravir) / Merck (MSD)
Trial completion, Combination therapy: Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients (clinicaltrials.gov) - Mar 30, 2014
P2, N=50, Completed, Sponsor: California Collaborative Treatment Group
Trial completion date: Apr 2014 --> Jul 2014 Active, not recruiting --> Completed
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment change: Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA (clinicaltrials.gov) - Mar 23, 2014
P1, N=25, Completed, Sponsor: Sanofi
Active, not recruiting --> Completed N=36 --> 25
- | efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion: Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA (clinicaltrials.gov) - Mar 23, 2014
P1, N=25, Completed, Sponsor: Sanofi
N=36 --> 25 Active, not recruiting --> Completed
- ||||||| Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion: Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Feb 27, 2014
P3b, N=799, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial completion: Study of the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults (clinicaltrials.gov) - Feb 23, 2014
P2, N=71, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||||| efavirenz / Generic mfg., emtricitabine/tenofovir disoproxil fumarate / Generic mfg., lamivudine/zidovudine / Generic mfg.
Trial completion, Combination therapy: Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects (clinicaltrials.gov) - Feb 22, 2014
P3, N=517, Completed, Sponsor: Gilead Sciences
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial: STATIS: Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3 (clinicaltrials.gov) - Feb 5, 2014
P4, N=1050, Not yet recruiting, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
- ||||| Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P4 trial, Adverse events: SWEAR: Switching From Efavirenz/Atripla to Rilpivirine Among Patients With Neurocognitive or Neuropsychological Side Effects (clinicaltrials.gov) - Jan 20, 2014
P4, N=90, Not yet recruiting, Sponsor: Azienda Ospedaliera San Gerardo di Monza
- efavirenz / Generic mfg., efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., nevirapine / Generic mfg.
Enrollment closed: A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy (clinicaltrials.gov) - Jan 9, 2014
P2, N=60, Active, not recruiting, Sponsor: University of Nebraska
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Pegasys (pegylated interferon ? -2a) / Roche, Isentress (raltegravir) / Merck (MSD)
Enrollment change: Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients. (clinicaltrials.gov) - Dec 19, 2013
P1/2, N=52, Completed, Sponsor: Gilead Sciences
Recruiting --> Active, not recruiting N=80 --> 52
- |||| Pegasys (pegylated interferon ? -2a) / Roche, Isentress (raltegravir) / Merck (MSD)
Trial completion: Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients. (clinicaltrials.gov) - Dec 19, 2013
P1/2, N=52, Completed, Sponsor: Gilead Sciences
N=80 --> 52 Active, not recruiting --> Completed
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion: High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART (clinicaltrials.gov) - Dec 4, 2013
P2, N=167, Completed, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||| Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Enrollment open, Head-to-Head: SALIF: A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (clinicaltrials.gov) - Oct 28, 2013
P3, N=426, Recruiting, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Isentress (raltegravir) / Merck (MSD)
Trial completion: SSAT036: Atripla to Raltegravir Switch Study for CNS Toxicity (clinicaltrials.gov) - Jul 30, 2013
P3, N=40, Completed, Sponsor: St Stephens Aids Trust
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Trial initiation date, IO biomarker, Metastases: Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS (clinicaltrials.gov) - Jul 24, 2013
P3, N=706, Recruiting, Sponsor: AIDS Clinical Trials Group
Recruiting --> Completed Initiation date: Feb 2013 --> Aug 2013
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Trial initiation date: SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) - Jul 10, 2013
P4, N=150, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Feb 2013 --> Aug 2013 Initiation date: Apr 2013 --> Jul 2013
- Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
Enrollment open: SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) - Jul 10, 2013
P4, N=150, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
Initiation date: Apr 2013 --> Jul 2013 Not yet recruiting --> Recruiting
- | Isentress (raltegravir) / Merck (MSD)
Trial completion: Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients (clinicaltrials.gov) - May 19, 2013
P4, N=30, Completed, Sponsor: Indiana University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Enrollment open: A-TRI-WEEK: Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (clinicaltrials.gov) - May 12, 2013
P4, N=60, Recruiting, Sponsor: Anna Cruceta
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P4 trial: Virological and immunological safety of a dose reduction strategy antiretroviral regimen with efavirenz / tenofovir / emtricitabine Seguridad virol (EUDRACT) - Apr 8, 2013
P4, N=60, Ongoing, Sponsor: Fundaci
- | Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P4 trial: SABES: HIV Test and Treat to Prevent HIV Transmission Among MSM and Transgender Women (clinicaltrials.gov) - Mar 19, 2013
P4, N=150, Recruiting, Sponsor: Fred Hutchinson Cancer Research Center
- || Tybost (cobicistat) / Gilead, Genvoya (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) / Gilead, Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate) / Gilead, Japan Tobacco
New P3 trial: Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants (clinicaltrials.gov) - Mar 19, 2013
P3, N=1500, Recruiting, Sponsor: Gilead Sciences
- Trial completion: ADVANZ-3: Once-daily Antiretroviral Therapy in HIV-1 Infected Patients With CD4+ Cell Counts Below 100 Cells/Mcl (clinicaltrials.gov) - Feb 20, 2013
P4, N=108, Completed, Sponsor: Juan A. Arnaiz
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Enrollment closed: A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine (clinicaltrials.gov) - Feb 19, 2013
P3, N=0, Active, not recruiting, Sponsor: St Stephens Aids Trust
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | efavirenz / Generic mfg., efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., nevirapine / Generic mfg.
New P2 trial: A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy (clinicaltrials.gov) - Feb 10, 2013
P2, N=60, Active, not recruiting, Sponsor: University of Nebraska
- Fuzeon (enfuvirtide) / Roche
Enrollment change, Metastases: A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy (clinicaltrials.gov) - Feb 6, 2013
P4, N=2, Completed, Sponsor: University of Maryland
Recruiting --> Active, not recruiting N=20 --> 2
- | efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
New P4 trial: A-TRI-WEEK: Virological and Immunological Safety of a Dose Reduction Strategy Antiretroviral Regimen With Efavirenz / Tenofovir / Emtricitabine (clinicaltrials.gov) - Jan 27, 2013
P4, N=60, Recruiting, Sponsor: Anna Cruceta
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Trial termination, Metastases: Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease (clinicaltrials.gov) - Jan 15, 2013
P4, N=15, Terminated, Sponsor: Rush University Medical Center
Recruiting --> Terminated; Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.
- efavirenz / Generic mfg., lopinavir/ritonavir / Generic mfg.
Enrollment change, Metastases: Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease (clinicaltrials.gov) - Jan 15, 2013
P4, N=15, Terminated, Sponsor: Rush University Medical Center
Only 15 of 60 needed enrolled. N=60 --> 15
- stavudine / Generic mfg., zidovudine / Generic mfg.
Enrollment open, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - Dec 16, 2012
P4, N=70, Recruiting, Sponsor: Tufts University
N=60 --> 15 Not yet recruiting --> Recruiting
- | Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
Trial completion: Study to Evaluate Switching From a Regimen Consisting of the Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate Single-Tablet Regimen (STR) to the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate STR (clinicaltrials.gov) - Dec 12, 2012
P2b, N=50, Completed, Sponsor: Gilead Sciences
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Isentress (raltegravir) / Merck (MSD)
Trial completion: Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection (clinicaltrials.gov) - Dec 12, 2012
P4, N=20, Completed, Sponsor: University of Alabama at Birmingham
Active, not recruiting --> Completed Recruiting --> Completed
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg.
Trial completion, Adherence: Adherence-Suppression-Resistance Relationships for Atripla Compared to Historical Antiretroviral Regimens (clinicaltrials.gov) - Nov 19, 2012
P=N/A, N=51, Completed, Sponsor: University of California, San Francisco
Recruiting --> Completed Active, not recruiting --> Completed
- efavirenz/emtricitabine/tenofovir disoproxil fumarate / Generic mfg., pravastatin / Generic mfg.
Trial suspension: Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation (clinicaltrials.gov) - Oct 23, 2012
P2, N=225, Suspended, Sponsor: AIDS Clinical Trials Group
Active, not recruiting --> Completed Recruiting --> Suspended
- Isentress (raltegravir) / Merck (MSD)
Trial withdrawal: A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells (clinicaltrials.gov) - Oct 22, 2012
P4, N=0, Withdrawn, Sponsor: Community Research Initiative of New England
Recruiting --> Suspended Active, not recruiting --> Withdrawn
- Isentress (raltegravir) / Merck (MSD)
Enrollment change: A Pilot Study to Determine if Raltegravir Eradicates HIV From Peripheral Blood Mononuclear Cells (clinicaltrials.gov) - Oct 22, 2012
P4, N=0, Withdrawn, Sponsor: Community Research Initiative of New England
Active, not recruiting --> Withdrawn N=15 --> 0
- |||||||||| Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P3 trial, Head-to-Head: SALIF: A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment (clinicaltrials.gov) - Oct 15, 2012
P3, N=426, Recruiting, Sponsor: Janssen-Cilag International NV
- Edurant (rilpivirine) / J&J, Complera (emtricitabine/rilpivirine/tenofovir) / Gilead, J&J
New P3 trial: A Pilot Study to Assess the Feasibility of Switching, Individuals Receiving Atripla With Continuing Central Nervous System (CNS) Toxicity, to a Fixed Dose Combination of Tenofovir/Emtricitabine/Rilpivirine (clinicaltrials.gov) - Oct 3, 2012
P3, N=0, Active, not recruiting, Sponsor: St Stephens Aids Trust
- | stavudine / Generic mfg., zidovudine / Generic mfg.
New P4 trial, HEOR, Cost effectiveness: Economic, Clinical and Quality of Life Assessment in Patients on Antiretroviral Therapy (clinicaltrials.gov) - Sep 24, 2012
P4, N=70, Recruiting, Sponsor: Tufts University